International Symposium on Personalized Cancer Care;
What have we achieved since 2012 in risk prediction, early diagnosis, progression, and therapy?
Oslo, May18-20, 2016, Holmenkollen Park Hotel Conference Center
Opening keynote on P4 and Cancer: Leroy Hood, Institute for Systems Biology, Seattle, USA
Speakers: 30 min followed by 10 min discussions to interact with the audience
Session I: Genetic Profiling of Patients, Prediction of Risk and therapy response
Bruce Ponder, Cancer Research Institute, Cambridge, UK
Paul Pharoah, Strangeways Research Laboratory, Cambridge, UK
Session II: Molecular Profiling of Tumors and Metastases
Elaine Mardis, The Genome Inst., Washington Univ., St. Louis, Missouri, USA
Zoltan Szallasi, Technical University of Denmark
Carlos Caldas, Cancer Research Inst. Cambridge UK.
Nicholas Navin, MD Anderson Cancr Center, Houston USA
Peter van Loo, Crick Center, London, UK
Session III: Tumor-host Microenvironment Interaction and Metabolism
Arnold Levine, Princeton University, USA
Larry Norton, Memorial Sloan-Kettering Cancer Center, NY; USA.
Mina Bissell, Lawrence Berkeley National Laboratory, CA, USA
Morag Park, McGill University, Montreal, Canada
Session IV: Targeted Therapy
Gordon Mills, MD Anderson Cancer Center, Houston USA
Rene Bernards, The Netherlands Cancer Institute, Netherlands
Joe Gray, Knight Cancer Inst. Oregon Health & Science Univ., Oregon USA
Alberto Bardelli, University of Torino, Italy
Soldano Ferrone, Massachusetts General Hospital, Harvard, Boston, USA
Session VI: Translation
Olli Kallioniemi, FIMM, Helsinki, Finland
Laura van't Veer, University of California, San Francisco, USA
Per Eystein Lønning, Univ Bergen, Norway
Anne-Lise Børresen-Dale, Oslo Univ Hopsital, Norway
Session V: The impact of social andethical issues on personalized medicine
Serena Nik-Zainal, Sanger Center, Hinxton, Cambridge, UK
David Livingstone, Dana-Farber Cancer Institute; Boston, USA